XML 46 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (USD $)
Sep. 30, 2012
Sep. 30, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 3,377,288 $ 7,507,389
Trade receivable 9,375  
Other receivables 9,930 1,608,382
Prepaid expenses and other current assets 618,130 110,818
Marketable securities 106,500 634,585
Note receivable, net 2,446,113  
TOTAL CURRENT ASSETS 6,567,336 9,861,174
PROPERTY AND EQUIPMENT    
Computers, office equipment and furniture 323,376 285,266
Research equipment 3,319,027 3,515
Software 69,623 77,020
Leasehold improvements 2,749,409  
Property, Plant and Equipment, Gross, Total 6,461,435 365,801
Less: Accumulated depreciation and amortization (1,565,783) (340,364)
PROPERTY AND EQUIPMENT, NET 4,895,652 25,437
OTHER ASSETS    
Patents and other intangible assets, net 4,784,569 1,731,211
Note receivable, net   2,272,868
Investment in Nanotope Inc., equity basis   1,649,748
Investment in Leonardo Biosystems Inc., at cost   187,000
Derivative asset and other non-current assets 280,261 161,125
TOTAL OTHER ASSETS 5,064,830 6,001,952
TOTAL ASSETS 16,527,818 15,888,563
CURRENT LIABILITIES    
Accounts payable 877,986 576,809
Accrued expenses 730,775 864,511
Accrued payroll and benefits 1,127,219 195,649
Deferred revenue 37,500  
Derivative liabilities 647,213 944,980
Capital lease obligation 214,801  
Other current liabilities 1,692,394  
TOTAL CURRENT LIABILITIES 5,327,888 2,581,949
LONG-TERM LIABILITIES    
Note payable, net of current portion 839,421 606,786
Capital lease obligation, net of current portion 1,282,458  
Other non-current liabilities 269,142 135,660
TOTAL LONG-TERM LIABILITIES 2,391,021 742,446
Commitments and contingencies      
STOCKHOLDERS' EQUITY    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding      
Common stock, $ 0.001 par value; 145,000,000 shares authorized; 13,579,185 and 8,642,286 shares issued and outstanding as of September 30, 2012 and September 30, 2011, respectively 108,354 86,423
Additional paid-in capital 145,917,968 127,476,435
Subscription receivable (1,016,000) (900,000)
Accumulated deficit during the development stage (134,997,680) (113,871,752)
Total Arrowhead Research Corporation stockholders' equity 10,012,642 12,791,106
Noncontrolling interest (1,203,733) (226,938)
TOTAL STOCKHOLDERS' EQUITY 8,808,909 12,564,168
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 16,527,818 $ 15,888,563